Content continues after advertisement

Research Note: Predicting Heart Failure or Cardiac Death in Dogs with Preclinical Myxomatous Mitral Valve Disease


|October 2021

Sign in to Print/View PDF

This prospective, placebo-controlled study of 168 dogs with preclinical myxomatous mitral valve disease (MMVD) and cardiomegaly assessed the ability of echocardiographic values and cardiac biomarkers (ie, N-terminal pro brain natriuretic peptide [NTproBNP], cardiac troponin I) to help predict the risk for heart failure or cardiac death. A composite of 3 variables (left atrium:aortic root ratio, early transmitral peak velocity, and NTproBNP value) was significantly associated with increased risk for heart failure or cardiac death and represents a useful predictive model. Results of this study may provide a basis for future therapeutic interventions to delay the progression of MMVD.


For global readers, a calculator to convert laboratory values, dosages, and other measurements to SI units can be found here.

All Clinician's Brief content is reviewed for accuracy at the time of publication. Previously published content may not reflect recent developments in research and practice.

Material from Clinician's Brief may not be reproduced, distributed, or used in whole or in part without prior permission of Educational Concepts, LLC. For questions or inquiries please contact us.


Clinician's Brief:
The Podcast
Listen as host Alyssa Watson, DVM, talks with the authors of your favorite Clinician’s Brief articles. Dig deeper and explore the conversations behind the content here.
Clinician's Brief provides relevant diagnostic and treatment information for small animal practitioners. It has been ranked the #1 most essential publication by small animal veterinarians for 9 years.*

*2007-2017 PERQ and Essential Media Studies

© 2023 Educational Concepts, L.L.C. dba Brief Media ™ All Rights Reserved. Terms & Conditions | DMCA Copyright | Privacy Policy | Acceptable Use Policy